As such, published on February 2, 2023 in Molecular Neurodegeneration, Wenger and colleagues used mass spectrometry to characterize the tau PTM landscape in two widely utilized mouse models of tauopathy (hTau.P301S and rTg4510), and subsequently compared this profile with both FTD patients carrying P301L mutations [5] and AD patients using their previous dataset [4]. The gene discussed is MAPT; the disease is Alzheimer disease.